Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
ARVO 2014 Annual Meeting Abstracts 516 Antimicrobials Thursday, May 08, 2014 8:30 AM–10:15 AM Exhibit/Poster Hall SA Poster Session Program #/Board # Range: 5783–5792/B0208–B0217 Organizing Section: Physiology/Pharmacology Program Number: 5783 Poster Board Number: B0208 Presentation Time: 8:30 AM–10:15 AM INNOVATIVE AQUEOUS AZITHROMYCIN OPHTHALMIC FORMULATION Maria G. Saita, Danilo Aleo, Sergio Mangiafico, Barbara Melilli, Melina G. Cro, Sebastiano Mangiafico. R&D, Medivis, Catania, Italy. Purpose: Azithromycin (AZM) is a semi-synthetic macrolide antibiotic largely employed as topical formulation to cure ocular surface infections. Unfortunately, AZM is unstable and practically insoluble in water. In fact, commercial formulations of AZM stable at room temperature are available only in oily vehicle, if a water vehicle is employed the product has to be refrigerated. Our aim was to develop an aqueous mucoadhesive AZM formulation stable at room temperature. Methods: The new formulation of AZM (MDV 1226) was prepared by adding 1.5% of AZM dihydrate, in a solution of appropriate cyclodextrin, to an isosmolar buffer solution (pH=6.7-7.2). The mucoadhesive Hyaluronic Acid was added to improve precorneal residence time of MDV 1226 on the ocular surface. Stability studies were performed under different ICH recommended conditions at 25°C and 40°C. Concentrations (%) of AZM (evaluated by HPLC), pH and Osmolality of the formulation were controlled for 12 months. Moreover a comparative stress thermal study at 70°C was conducted in comparison to commercial topical aqueous formulation of Azithromycin (Azasite). Results: Stability study conducted at 70°C showed that AZM in MDV 1226 was more stable than AZM in Azasite: after 2 weeks concentration of AZM in the two formulations was 70% in MDV 1226 and only 17% in Azasite. Stability study under ICH recommended conditions showed that AZM in MDV1226 at 25°C was 99% after 12 months and 80% at 40°C after 6 months. The main degradation pattern of AZM was elucidated by HPLC-MS and concerns the hydrolysis of sugar at C-3 (L-Cladinose) of AZM lactone to conduct at descladinose azithromycin (DAZM). Osmolality and pH in MDV 1226 were maintained stable for 12 months. Conclusions: Stability studies showed that no significant changes were observed with respect to pH, Osmolality and concentration of AZM in MDV 1226 for 12 months at room temperature. The presence of the mucoadhesive Hyaluronic Acid in MDV 1226 should guarantee better performance of the topical AZM. Pharmacokinetics studies in rabbits are on going. Commercial Relationships: Maria G. Saita, Medivis (E); Danilo Aleo, Medivis (E); Sergio Mangiafico, Medivis (E); Barbara Melilli, Medivis (E); Melina G. Cro, Medivis (E); Sebastiano Mangiafico, Medivis (E) Program Number: 5784 Poster Board Number: B0209 Presentation Time: 8:30 AM–10:15 AM Correlation of Phenotypic Expression of Methicillin Resistance with Genotype and In Vitro Susceptibility for mecA+ Staphylococcus epidermidis Endophthalmitis Isolates Laura C. Huang1, Jack Stringham2, James Wong1, Jorge Maestre2, Darlene Miller2, Harry W. Flynn2. 1University of Miami Miller School of Medicine, Miami, FL; 2Bascom Palmer Eye Institute, Miami, FL. Purpose: To correlate the genotypic methicillin resistance conferred by the mecA gene with phenotypic expression of methicillin resistance among Staphylococcus (S) epidermidis isolates from endophthalmitis and in vitro susceptibility to ceftaroline, a new fifth generation cephalosporin, and other commonly used antimicrobials. Methods: Etests and the VITEK 2 system were used to detect the presence and phenotypic expression of methicillin resistance among S. epidermidis isolates recovered from endophthalmitis. Results were compared with mecA genotype using polymerase chain reaction (PCR) and in vitro susceptibility to ceftaroline and vancomycin (Etests) and VITEK 2 breakpoints for gentamicin, daptomycin, linezolid, tigecycline, levofloxacin, and moxifloxacin. Additionally, antibiotic susceptibility was analyzed against the following subgroups: mecA+ with methicillin resistance (group A) and isolates that were mecA+ though clinically methicillin sensitive (group B). Results: All 32 isolates recovered from 2010-2013 were mecAgenotype positive (100%), however, only 21/32 (65.6%) expressed methicillin resistance by conventional laboratory tests. Isolates were 100% susceptible to vancomycin (MIC90 3 μg/mL, N=32), ceftaroline (MIC90 0.38 μg/mL, N=32), linezolid (N=20), and tigecycline (N=20). The susceptibility of daptomycin (N=20) was 95%. Gentamicin susceptibility overall was 86.7% (26/30) of which group A had 78.9% (15/19) susceptible compared to 100% (11/11) in group B. A correlation between the phenotypic expression of mecA genotype and in vitro susceptibility was demonstrated for the fluoroquinolones. For levofloxacin, group A had 21.1% (4/19) susceptible in contrast to 81.8% (9/11) (p=0.001) in group B. For moxifloxacin, group A had 30% (3/10) susceptible compared to 80% (8/10) (p=0.025) in group B. Conclusions: Routine laboratory methods may fail to detect heterogeneous and or low level expression of methicillin resistance among mecA+ S. epidermidis genotypes. This may have important implications for the correct selection and management of S. epidermidis endophthalmitis. The new fifth generation cephalosporin, ceftaroline, demonstrated low MIC values and may show promise as a therapeutic agent for methicillin resistant S. epidermidis. Commercial Relationships: Laura C. Huang, None; Jack Stringham, None; James Wong, None; Jorge Maestre, None; Darlene Miller, None; Harry W. Flynn, None Support: NIH Center Core Grant P30EY014801, Research to Prevent Blindness Unrestricted Grant, Department of Defense (DODGrant#W81XWH-09-1-0675). Program Number: 5785 Poster Board Number: B0210 Presentation Time: 8:30 AM–10:15 AM Bactericidal Activity of Levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an In Vitro Pharmacokinetic Model Simulating Concentration in the Bulbar Conjunctiva after Eye Drop Takashi Suzuki, Toshihiro Yamamoto, Yuichi Ohashi. Ophthalmology, Ehime University School of Medicine, Toon, Japan. Purpose: The aim of this work was to compare the pharmacological properties of levofloxacin (LVFX) against Staphylococcus aureus and Staphylococcus epidermidis by pharmacokinetic (PK) model simulating concentration in the bulbar conjunctiva after eye drop of 0.5% and 1.5% LVFX. Methods: The strains used were S. aureus and S. epidermidis conjunctival sac isolates which minimum inhibitory concentrations (MICs) of LVFX were 0.25 and 0.125 μg/ml, respectively. The LVFX resistant strains were made from their parental strains by culture with LVFX. The in vitro PK model simulated the concentration of the bulbar conjunctiva following topical application of 0.5 or 1.5% LVFX ophthalmic solution three times (0, 4 and 8 hour) to rabbit ©2014, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permission to reproduce any abstract, contact the ARVO Office at [email protected]. ARVO 2014 Annual Meeting Abstracts eyes. Parental and LVFX resistant strains were exposed to LVFX in an in vitro PK model, and changes in viable bacterial counts were evaluated over the course of 12h. Results: MICs of LVFX in resistant isolates increased from 2 to 32 times of parental strains (S. aureus; 0.5-2μg/ml, S. epidermidis; 0.54μg/ml) after induction of LVFX resistance. LVFX was bactericidal against all tested strains which MICs included highest value, in PK model simulating use of 1.5% LVFX ophthalmic solution. In contrast, simulation of 0.5% LVFX eye drop showed LVFX was bactericidal against isolates which MICs were as follows: (S. aureus; 0.25-0.5μg/ ml, S. epidermidis; 0.125-1μg/ml). Conclusions: In vitro PK model simulating concentration in the bulbar conjunctiva after LVFX eye drop demonstrated 1.5% LVFX ophthalmic solution had stronger bactericidal effects against Staphylococci in the bulbar conjunctiva than 0.5% LVFX ophthalmic solution. Commercial Relationships: Takashi Suzuki, Santen Pharmaceutical Co., Ltd (F); Toshihiro Yamamoto, Santen Pharmaceutical Co., Ltd (F); Yuichi Ohashi, Santen Pharmaceutical Co., Ltd (F) Support: This was collaborative research with Santen Pharmaceutical Co., Ltd. Program Number: 5786 Poster Board Number: B0211 Presentation Time: 8:30 AM–10:15 AM Cytotoxicity of Ophthalmic Antimicrobial Solutions on SV40immortalized Human Corneal Epithelial Cells Jae Lim Chung1, Young A Kwon1, Sang Wroul Song1, Byung Yeop Kim1, Joon H. Lee1, Kyoung Yul Seo2, Christopher Ta3. 1 Ophthalmology, Myung-Gok Eye Research Institute, Kim’s Eye Hospital, Konyang University College of Medicine, Seoul, Republic of Korea; 2Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Republic of Korea; 3 Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA. Purpose: To enhance the pharmacokinetic properties of ophthalmic antimicrobials, high-concentration of active ingredient or surfaceretentive delivery system are being used. However, ocular toxicity is a concern when using these agents. In this study, we evaluated the cytotoxicity of various ophthalmic antibiotics on SV40-immortalized human corneal epithelial cells using the 3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Methods: We tested original and 10-fold diluted solutions of Cravit (levofloxacin 0.5%), Cravit 1.5 (levofloxacin 1.5%), Quixin (levofloxacin 0.5%, Benzalkonium chloride (BAK) 0.005%), Iquix (levofloxacin 1.5%), Vigamox (moxifloxacin 0.5%), Moxeza (moxifloxacin 0.5%, xanthan gum), Gatiflo (gatifloxacin 0.3%), Zymaxid (gatifloxacin 0.5%, BAK 0.005%), Besivance (besifloxacin, BAK 0.01%, durasite), Azasite (azithromycin 1%, BAK 0.003%, durasite), Tobrex (tobramycin 0.3%, BAK 0.01%). We also tested using standard material powders of each drug to rule out the effect of other components in ophthalmic solutions. The MTS assay was performed after 5 to 120 minutes of exposure to each solution. According to the cell survival score, we graded the cytotoxicity as mild(over 75%), moderate(50~75%) and marked(below 50%). Results: Following exposure to undiluted solutions, cell viabilities were decreased to 9~73% after 5 minutes. After 30 minutes Tobrex, Zymaxid and Quixin showed marked toxicity, Cravit 1.5, Iquix and Vigamox showed moderate toxicity and Cravit and Gatiflo showed mild toxicity. When exposed to 10-fold diluted solutions, Tobrex, Besivance, Zymaxid, Quixin and Azasite, which were BAK containing products, showed moderate toxicity. After exposure to standard powder solutions, 0.6% besifloxacin, 0.5% gatifloxacin, 0.5% moxifloxacin, 1.5% levofloxacin and 0.5% levofloxacin showed moderate toxicity in decreasing order. However, 1% azithromycin and 0.3% tobramycin standard powder solutions showed the least toxicity. Conclusions: High concentration alone did not further increase cytotoxicity. The most important factor for the determination of cytotoxicity was the concentration of BAK in antimicrobial solutions. Commercial Relationships: Jae Lim Chung, None; Young A Kwon, None; Sang Wroul Song, None; Byung Yeop Kim, None; Joon H. Lee, None; Kyoung Yul Seo, None; Christopher Ta, None Program Number: 5787 Poster Board Number: B0212 Presentation Time: 8:30 AM–10:15 AM 5% Betadine solution in not effective in inhibiting the growth of different Gram Negative and Gram Positive Pathogens in vitro Eric Huynh1, Phat Tran1, 2, Patrick Pham1, Abdul Hamood2, Kelly Mitchell1, Ted W. Reid1, 2. 1Ophthalmology and Visual Sciences, Texas Tech Univ Health Sciences Ctr, Lubbock, TX; 2Immunology and Molecular Microbiology, Texas Tech University Health Sciences Ctr, Lubbock, TX. Purpose: Injections of intravitreal medications has become routine care in ophthalmology offices throughout the world for the treatment of several retinal diseases. Studies estimate that the rate of endophthalmitis form intraocular injections range from 1.67% to 0.006%. Currently, 5% providone-iodine (Betadine) is widely accepted as the main antisepsis used to decrease this risk. Thus, the present study was undertaken to measure the effectiveness of 5% Betadine in inhibiting the growth of both Gram negative and Gram positive bacteria. Methods: Betadine disks were prepared by adding 20 μl of 5% Betadine solution onto each 6 mm diameter BBL blank paper disk. LB Agar plates were inoculated with a confluent lawn of bacteria, made on each plate using cotton swabs dipped into 107 CFU/ml of the bacterial suspensions. Within 15 min after the plates were inoculated, Betadine disks were distributed evenly onto the LB Agar surface, with at least 24 mm (center to center) between them. The plates were incubated at 37oC for 24 h before results were read. The diameters of the zones of complete inhibition, including the diameter of the disk, were measured to the nearest millimeter with a ruler. In addition, the remaining microorganisms on the disks were quantified by the CFU assay. All experiments were done in triplicate, and all measurements were repeated three times. The bacteria tested were Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, Streptococcus salivarius, Streptococcus mutans, Staphylococcus epidermidis, and Serratia marcescens. Results: All the bacteria, except Pseudomonas aeruginosa, showed zones of inhibition against the lawns of bacteria. However, when the disks were tested for bacteria after the zone of inhibition study was completed, only three of the eight different bacteria showed killing of the bacteria on the disk. These were, one gram negative bacteria, Serratia marcescens, and two gram positive bacteria, Streptococcus salivarius, and Streptococcus mutans. Conclusions: The two main conclusions are: 1) the zone of inhibition assay does not give a realistic assessment of the ability of an antimicrobial to kill bacteria; and 2) In vitro, 5% Betadine does not appear to be effective at killing the bacterial species associated with post procedure endophthalmitis. Commercial Relationships: Eric Huynh, None; Phat Tran, None; Patrick Pham, None; Abdul Hamood, None; Kelly Mitchell, None; Ted W. Reid, None ©2014, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permission to reproduce any abstract, contact the ARVO Office at [email protected]. ARVO 2014 Annual Meeting Abstracts Program Number: 5788 Poster Board Number: B0213 Presentation Time: 8:30 AM–10:15 AM Effect of biguanide on excystment, proliferation and death of Acanthamoeba strains Marina Roizenblatt, Linda C. Carrijo-Carvalho, Annette S. Foronda, Fabio R. Carvalho, Denise Freitas. Department of Ophthalmology and Visual Sciences, Paulista School of Medicine, São Paulo Hospital, Federal University of São Paulo, São Paulo, Brazil. Purpose: Acanthamoeba keratitis is a sight-threating infection which can progress into the eye, causing corneal ulcer, loss of visual acuity and eventually blindness. There is a lack of a standard therapy. The treatment is based on topical instillation of biguanides and/ or diamidines at higher concentration and these compounds seems to be toxic to corneal cells. The present study was designed to investigate the antimicrobial activity of a biguanide, at a lower concentration, against Acanthamoeba cysts isolated from a severe AK case, comparing the susceptibility pattern with an avirulent strain of the protozoa. Methods: The study was approved by the local ethics committee. The effect of polyhexamethylene biguanide (PHMB) at 0.02% was evaluated in an avirulent Acanthamoeba strain (ATCC 30011) and a clinical isolate. Induction of death, excystment and proliferation of protozoa at 12 and 72 h were evaluated by quantitative analysis. The experimental procedures were carried out in triplicate. Data were subjected to one-way ANOVA and results were considered statistically significant when p < 0.05. Results: Our findings demonstrated a reduction of 44.5 and 61.6% in the total number of trophozoites from ATCC 30011 and clinical isolate, respectively, at the time of 12 h. After 72 h, the reduction was 94.9 and 85.4% for ATCC 30011 and the clinical isolate, respectively. Avirulent strain and clinical isolate were equally susceptible to PHMB at 12 h, while the clinical isolate showed increased resistance to PHMB action after 72 h, with a high viability rate. Conclusions: Differential patterns of resistance against PHMB were demonstrated between Acanthamoeba strains. Data suggest the hypothesis of PHMB acts in the viability and proliferation of trophozoites and not in the inhibition of excystment of the protozoa. Our findings demonstrates the importance of an earlier and specific therapeutic profile and the key role of patient in regular usage of PHMB in order to avoid the eventual occurrence of acquired resistance strain during the treatment for AK. Finally, the results open perspectives about the dosage and frequency of PHMB 0.02% to be used in the treatment of AK. Commercial Relationships: Marina Roizenblatt, None; Linda C. Carrijo-Carvalho, None; Annette S. Foronda, None; Fabio R. Carvalho, None; Denise Freitas, None Program Number: 5789 Poster Board Number: B0214 Presentation Time: 8:30 AM–10:15 AM Corneal Pharmacokinetics of Meropenem Henri Sueke1, 2, Tim Neal1, Stephen J. Tuft3, Mark Wilkinson2, Yalin Zheng2, Craig Winstanley2, Stephen Kaye1, 2. 1Ophthalmology, Royal Liverpool University Hospital, Liverpool, United Kingdom; 2Eye and Vision Science, University of Liverpool, Liverpool, United Kingdom; 3 Ophthalmology, Moorfields Hospital, London, United Kingdom. Purpose: To evaluate the corneal pharmacokinetics of meropenem, a potentially novel antimicrobial in treating bacterial keratitis we quantify (1) the toxicity of meropenem compared to moxifloxacin on corneal cells in culture (2) the corneal penetration of meropenem across corneas mounted on artificial anterior chambers. Methods: Human keratocyte cells (HKCs) and human corneal epithelial cells (HCE-Ts) in culture, were treated with either 5mg/ ml or 2.5 mg/ml of meropenem or moxifloxacin for 1 hour. MTT cell viability assay was used to compare cell toxicity. Absorbance was read using an automated microplate reader and cell viability was expressed as percentages in relation to controls. Cell morphology of HKCs and HCE-Ts were assessed with fluorescent microscopy after incubation with meropenem compared to controls. Human cadaver corneas were used in corneal penetration experiments. Epithelium and endothelium were removed mechanically and corneas were mounted onto artificial anterior chambers. 10mg/ml of meropenem was inserted onto the corneas and samples of fluid in the artificial anterior chamber were removed at 45minutes, 1.5hrs, 3.5hrs and 24hrs. Meropenem concentrations were estimated from corneal homogenate and anterior chamber samples using; (1) disc diffusion bioassay measuring zones of inhibition when samples incubated with Escherichia Coli on agar plates and (2) reverse-phase High-Performance Liquid Chromatography (HPLC). Results: MTT assays of HCE-T and HKC cells showed meropenem had significantly higher cell viability at both 5mg/ml and 2.5mg/ml compared to moxifloxacin p<0.05. Cell morphology of meropenem was indistinguishable from controls. Graph 1 summarises the diffusion of meropenem across 18 corneas. The mean corneal penetration of meropenem even at the earliest sampling point (45 minutes) were 4 times higher than the MIC90 seen with meropenem against keratitis isolates in a previous study. Concentrations of meropenem were seen to increase steadily throughout the sampling time period. Meropenem concentrations measured with bioassay were much higher than HPLC measurements. Conclusions: We have previously shown meropenem to have excellent in vitro activity against both Gram positive and Gram negative isolates from patients with bacterial keratitis. This study suggests a good safety profile against corneal cells in culture. High corneal penetration of meropenem was seen at the earliest sampling point well in excess of the MIC90. Commercial Relationships: Henri Sueke, None; Tim Neal, None; Stephen J. Tuft, None; Mark Wilkinson, None; Yalin Zheng, None; Craig Winstanley, None; Stephen Kaye, None Program Number: 5790 Poster Board Number: B0215 Presentation Time: 8:30 AM–10:15 AM Besifloxacin Ophthalmic Suspension, 0.6% Compared with Gatifloxacin Ophthalmic Solution, 0.3% for the Treatment of Bacterial Conjunctivitis in Neonatal Patients Tuyen Ong1, Catherine Allaire3, Timothy W. Morris2, Baldo Sforzolini1. 1Clinical Development, Bausch & Lomb Incorporated, Madison, NJ; 2Microbiology and Sterilization Sciences, Bausch & Lomb Incorporated, Rochester, NY; 3European Pharmaceutical Clinical Science, Bausch & Lomb Incorporated, Evry Cedex, France. Purpose: To evaluate the safety and efficacy of topical besifloxacin ophthalmic suspension, 0.6% compared with gatifloxacin ophthalmic solution, 0.3% in the treatment of neonatal patients with bacterial conjunctivitis. Methods: Multicenter, randomized, double-masked, parallel group study. Patients ≤31 days of age with a severity of grade ≥1 conjunctival discharge and conjunctival hyperemia were randomized to besifloxacin or gatifloxacin instilled in the infected eye(s) 3 times daily for 7 days and completed 5 study visits (3 clinic visits and 2 ©2014, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permission to reproduce any abstract, contact the ARVO Office at [email protected]. ARVO 2014 Annual Meeting Abstracts phone calls). Primary endpoints included clinical resolution (absence of both conjunctival discharge and conjunctival hyperemia) at Visit 5 (Day 8 or 9) and rates of ocular and non-ocular treatment emergent adverse events (AEs). Microbial eradication was a secondary endpoint. Results: Thirty three patients (33 eyes) were randomized. Mean (±SD) age of patients was 15.5 (6.0) days and 57.6% were female. Of these, 22 patients (22 eyes) had culture-confirmed bacterial conjunctivitis, most often with gram-positive bacteria. Day 8 clinical resolution and microbial eradication appeared similar between treatment groups. One ocular AE considered unrelated to study treatment was reported (mild bacterial conjunctivitis in a treated fellow eye of a gatifloxacin-treated patient). There were no treatment related non-ocular AEs. Conclusions: In this study with neonatal patients, both besifloxacin and gatifloxacin appeared effective and safe in the treatment of bacterial conjunctivitis. Commercial Relationships: Tuyen Ong, Bausch & Lomb Incorporated (E); Catherine Allaire, Bausch & Lomb Incorporated (E); Timothy W. Morris, Bausch & Lomb Incorporated (E); Baldo Sforzolini, Bausch & Lomb Incorporated (E) Clinical Trial: 01330355 Program Number: 5791 Poster Board Number: B0216 Presentation Time: 8:30 AM–10:15 AM Optimizing fluence settings and riboflavin composition for collagen cross-linking (CXL) in the antimicrobial efficiency against Pseudomonas aeruginosa and Staphylococcus aureus. Olivier Richoz1, Florence Hoogewoud1, David Tabibian1, Arthur Hammer1, Farhad Hafezi1, 2. 1Ophthalmology, Geneva University Hospital, Geneva, Switzerland; 2Ophthalmology, Southern California, Doheny Eye Institute, Keck School of Medicine, Los Angeles, CA. Purpose: When treating bacterial keratitis, determination of the correct pathogen is often clinically challenging. The benefits of using CXL to treat corneal infections is that the treatment is not pathogenspecific. In an attempt to optimize the treatment parameters, we analyzed the effect of high fluence CXL on the bacterial killing rate in an in vitro model using Pseudomonas aeruginosa. Methods: The killing rate of a known concentration of bacterias (Pseudomonas aeruginosa and Staphylococcus aureus) was analyzed for the following conditions: 1) preservative-free riboflavin, with UV-A irradiation @ 18 mW/cm2 for 5 minutes 2) preservative-free riboflavin, with UV-A irradiation @ 36 mW/cm2 for 2.5 minutes 3) riboflavin with preservatives, with UV-A irradiation @ 18 mW/cm2 for 5 minutes 4) riboflavin with preservatives, with UV-A irradiation @ 36 mW/cm2 for 2.5 minutes 5) riboflavin only, no UVA 6) riboflavin with preservatives, no UVA. We used 0.1% riboflavin in all experiments. Results: The groups with preservative-free riboflavin showed a killing rate of 2 logs with 18 mW/cm2 and one log with 36 mW/cm2. The groups with riboflavine with preservatives showed a killing rate of 2 logs (98 %) with both fluences. Conclusions: The P. aeruginosa and S. aureus killing rate is fluence-dependent when using conventional riboflavin and fluenceindependent when preservatives are added to the riboflavin solution. These findings will allow the generation of optimized riboflavin solutions for the treatment of bacterial keratitis. Commercial Relationships: Olivier Richoz, Emagine AG (I), Emagine AG (P), Emagine AG (S); Florence Hoogewoud, None; David Tabibian, None; Arthur Hammer, None; Farhad Hafezi, Emagine AG (I), Emagine AG (P), Emagine AG (S) Support: The Swiss National Science Foundation MD-PhD grant Program Number: 5792 Poster Board Number: B0217 Presentation Time: 8:30 AM–10:15 AM Comparative Anti-Fungal Susceptibility Analysis of Candida Albicans versus Non-Albicans Candida Corneal Isolates Oriel Spierer, Jyoti R. Dugar, Darlene Miller, Terrence P. O’Brien. Ophthalmology, Bascom Palmer Eye Institute, Palm Beach Gardens, FL. Purpose: To compare in vitro topical amphotericin B (AMB), natamycin, voriconazole and fluconazole in the treatment of Candida keratitis. Methods: Seventy two candida isolates (36 albicans and 36 nonalbicans isolates) recovered from corneal scrapings submitted to rule out microbial keratitis, during the years 2005-2011, at the Bascom Palmer Eye Institute, were examined. Corneal isolates were cultured on fungal agars for 48 hours. Each yeast isolate was dispensed into 4 microtiter wells, each containing 100 microliter of commercial (natamycin 5%) or compounded (AMB 0.15%, voriconazole 1% and fluconazole 0.2%) antifungal medications. Microtiter plates were incubated at 30 °C and monitored for growth or inhibition at 48 hours. A comparison of growth patterns was done. Results: One hundred percent of the samples showed growth inhibition after treatment with AMB or natamycin. The isolates treated with voriconazole presented 85% inhibition rate overall, with the Candida albicans samples showing 77% inhibition rate and the non-albicans 93% inhibition rate. In the fluconazole group only 19.6% inhibition rate was noted, with 7.7% inhibition rate in the Candida albicans group versus 30% inhibition rate in the nonalbicans group. Conclusions: AMB 0.15% and natamycin 5% have equal effectiveness and full inhibition against Candida keratitis isolates. Fluconazole 0.2% is not the drug of choice in both Candida albicans and non-albicans keratitis. Voriconazole 1% may need a stronger concentration for higher effectiveness, but may be helpful as a second agent in the treatment of Candida keratitis. Commercial Relationships: Oriel Spierer, None; Jyoti R. Dugar, None; Darlene Miller, None; Terrence P. O’Brien, None Support: Supported by NIH Center Core Grant P30EY014801, Research to Prevent Blindness Unrestricted Grant, Department of Defense (DOD- Grant#W81XWH-09-1-0675) ©2014, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permission to reproduce any abstract, contact the ARVO Office at [email protected].